This Small Biotech Will Profit From the Hep C Drug Race

Gilead Sciences  (NASDAQ: GILD  )  and AbbVie  (NYSE: ABBV  )  are in a race to get the first all-oral hepatitis C treatment for patients infected with genotype 1 hepatitis C virus. Gilead's cocktail is already submitted to the Food and Drug Administration, and AbbVie expects to submit its application in the second quarter.

Currently, patients have to take an injected medication called peginterferon, which causes annoying side effects that feel like the flu, so the all-oral cocktails will be a huge step forward, rewarding Gilead and AbbVie handsomely for their efforts.

There's a third player in this race that doesn't get as much attention: Enanta Pharmaceuticals  (NASDAQ: ENTA  ) , which helped develop one of the components of AbbVie's cocktail. The small biotech will benefit through double-digit royalties on ABT-450. Watch the video below for more information on Enanta's potential.

And you thought the hepatitis C market was large...
Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 14, 2014, at 9:56 AM, JSYC wrote:

    Brian should be precise and accurate! It's MRSA (Methicillin Resistant Staphylococcus Aureus) and NOT MRSA!!

  • Report this Comment On March 14, 2014, at 9:58 AM, JSYC wrote:

    Oops, I meant MSRA as Brian said in his interview!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2875505, ~/Articles/ArticleHandler.aspx, 9/4/2015 5:26:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:00 PM
ABBV $59.77 Down -1.81 -2.94%
AbbVie Inc. CAPS Rating: ****
ENTA $38.87 Down -0.25 -0.64%
Enanta Pharmaceuti… CAPS Rating: ****
GILD $102.06 Up +0.15 +0.15%
Gilead Sciences CAPS Rating: *****